-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2579 Validation of Differentially Expressed Micrornas in Primary Immune Thrombocytopenia Suggests Mir-199a-5p Is a Potential Diagnostic Biomarker

Program: Oral and Poster Abstracts
Session: 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Biological Processes, molecular biology, pathogenesis
Sunday, December 10, 2023, 6:00 PM-8:00 PM

Lamya Garabet1,2*, Anbjørg Rangberg1*, Raul Teruel-Montoya, PhD3*, Maria Luisa Lozano, MD, PhD3*, Christine Monceyron Jonassen1,4* and Waleed Ghanima, MD, PhD5

1Center of Laboratory Medicine, Østfold Hospital, Grålum, Norway
2Department of Multidisciplinary Laboratory Medicine and Medical Biochemistry, Akershus University Hospital, Lørenskog, Norway
3Servicio de Hematología, Hospital General Universitario Morales Messeguer, Centro Regional de Hemodonación, IMIB-Pascual Parrilla, CIBERER-ISCIII, Universidad de Murcia, Murcia, Spain
4Department of Virology, Norwegian Institute of Public Health, Oslo, Norway
5Østfold Hospital, Gralum, Norway


Currently, there is no specific diagnostic test for immune thrombocytopenia (ITP). MicroRNAs (miRNA) are small, noncoding RNAs involved in the post-transcriptional regulation of gene expression. Aberrant expression of miRNAs has been suggested to have potential diagnostic value. Previous explorative studies have identified several differentially expressed miRNAs in ITP with potential diagnostic value; however, such findings are usually difficult to reproduce. Therefore, we aimed to validate some of these miRNAs in a larger ITP cohort.


Based on previous studies in ITP, we selected 12 miRNAs for validation in patients with primary ITP. The following miRNA were selected: miR-199a-5p, miR-33a-5p, miR-195-5p, miR-130a-3p, miR-144-3p, miR-146a-5p, miR-222-3p, miR-374-5p, miR-486-5p, miR-1341-5p, miR-766-3p, miR-409-3p. Blood samples (n=61) were obtained from 2 cohorts of primary ITP and healthy controls. The first cohort included samples from 24 patients with newly diagnosed or persistent ITP from the PROLONG study (NCT00344149); all patients had been treated with corticosteroids +/- IVIG but relapsed or failed to respond. The second cohort included 37 samples obtained from the ITP biobank at Østfold Hospital, Norway; patients had different disease phases and had received different therapies. In addition, 28 samples were obtained from healthy controls.

The miRNAs were quantified in citrated plasma using droplet digital PCR (Bio-Rad).


The mean age of the ITP patients was 51 years (62% female) and of the controls 47 years (64% female). The mean platelet count for all patients was 48.8 ·109/L. PROLONG patients had a lower mean platelet count (33 ·109/L) than patients from ITP biobank (59 ·109/L).

Mann-Whitney test showed that miR-199a-5p (p=0.001), miR-33a-5p (p=0.010), miR-374-5p (p=0.009) and miR-146a-5p (p=0.026) were significantly differentially expressed (downregulated) in ITP compared with controls. Subgroup analysis of PROLONG patients showed that 3 additional miRNAs (7 of the 12 miRNAs) were significantly differentially expressed (downregulated) in these ITP patients: miR-130a-3p (p=0.005), miR-766-3p (p=0.010) and miR-409-3p (p=0.001).

ROC curve analysis showed good discrimination for miR-199a-5p in all patients with an AUC of 0.718 (95% CI 0.599-0.836), and satisfactory for miR-33a-5p with an AUC of 0.671 (CI 0.549-0.793), 0.673 (CI 0.554-0.792) for miR-374-5p and 0.632 (CI 0.505-0.759) for miR-409-3p (Figure A).

Subgroup analysis for each of the two cohorts separately showed higher AUC in PROLONG patients for miR-199a-5p (AUC=0.824; 95% CI 0.708-0.940), miR-374-5p (AUC=0.806; 95% CI 0.688-0.924), and for miR-33a-5p (AUC=0.732; 95% CI 0.597-0.868). The combination of all three miRNAs: miR-199a-5p, miR-33a-5p and miR-374-5p in PROLONG patients resulted in a slight improvement of the AUC to 0.865 (CI 0.767-0.962) (Figure B).


This study confirms that miR-199a-5p, miR-33a-5p, miR-374-5p and miR-146a-5p are differentially expressed in primary ITP compared with healthy controls. miR-199a-5p shows a good ability to discriminate primary ITP patients from healthy controls. In the PROLONG cohort, both miR-199a-5p and miR-374-5p showed a very good discrimination, probably due to the fact that these patients had early ITP. These findings should be further validated in a prospective cohort of newly diagnosed ITP patients and in patients with other types of thrombocytopenia to explore their potential diagnostic value. Some of these miRNAs have important regulatory functions, particularly in inflammation and apoptosis, so it is essential to evaluate their function and role in the pathogenesis of ITP and their potential use as therapeutic targets.

Disclosures: Garabet: Grifols: Honoraria. Ghanima: Bayer: Consultancy, Honoraria, Research Funding; Sanofi: Consultancy, Honoraria; BMS: Honoraria, Research Funding; Argenx: Consultancy, Honoraria; Grifols: Consultancy, Honoraria; hibio: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; cellphire: Consultancy, Honoraria; alpine: Consultancy, Honoraria; Sobi, Pfizer: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria; Kedrion: Consultancy; UCB: Consultancy, Honoraria.

*signifies non-member of ASH